Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Benefits of cryopreserved human amniotic membranes in association with conventional treatments in the management of full-thickness burns.

Hatzfeld AS, Pasquesoone L, Germain N, Danzé PM, Drucbert AS, Tardivel M, Bongiovanni A, Duquennoy-Martinot V, Guerreschi P, Marchetti P.

Int Wound J. 2019 Aug 19. doi: 10.1111/iwj.13198. [Epub ahead of print]

PMID:
31429202
2.
3.

Comparison of Gene Expression in Human Embryonic Stem Cells, hESC-Derived Mesenchymal Stem Cells and Human Mesenchymal Stem Cells.

Barbet R, Peiffer I, Hatzfeld A, Charbord P, Hatzfeld JA.

Stem Cells Int. 2011;2011:368192. doi: 10.4061/2011/368192. Epub 2011 Aug 29.

4.

Optimization of physiological xenofree molecularly defined media and matrices to maintain human embryonic stem cell pluripotency.

Peiffer I, Barbet R, Hatzfeld A, Li ML, Hatzfeld JA.

Methods Mol Biol. 2010;584:97-108. doi: 10.1007/978-1-60761-369-5_5.

PMID:
19907973
5.

[bFGF-stimulated MEF-conditioned medium is capable of maintaining human embryonic stem cells].

Zhou YP, Rochat A, Hatzfeld A, Peiffer I, Barbet R, Hatzfeld J, Li ML.

Fen Zi Xi Bao Sheng Wu Xue Bao. 2009 Jun;42(3-4):193-9. Chinese.

PMID:
19697701
6.

Use of xenofree matrices and molecularly-defined media to control human embryonic stem cell pluripotency: effect of low physiological TGF-beta concentrations.

Peiffer I, Barbet R, Zhou YP, Li ML, Monier MN, Hatzfeld A, Hatzfeld JA.

Stem Cells Dev. 2008 Jun;17(3):519-33. doi: 10.1089/scd.2007.0279.

PMID:
18513159
7.

Simultaneous differentiation of endothelial and trophoblastic cells derived from human embryonic stem cells.

Peiffer I, Belhomme D, Barbet R, Haydont V, Zhou YP, Fortunel NO, Li M, Hatzfeld A, Fabiani JN, Hatzfeld JA.

Stem Cells Dev. 2007 Jun;16(3):393-402.

PMID:
17610369
8.

A sub-population of high proliferative potential-quiescent human mesenchymal stem cells is under the reversible control of interferon alpha/beta.

Peiffer I, Eid P, Barbet R, Li ML, Oostendorp RA, Haydont V, Monier MN, Milon L, Fortunel N, Charbord P, Tovey M, Hatzfeld J, Hatzfeld A.

Leukemia. 2007 Apr;21(4):714-24. Erratum in: Leukemia. 2007 Aug;21(8):1848.

PMID:
17375123
9.

[Human embryonic stem cells: practical problems and scientific potentialities].

Hatzfeld A, Peiffer I, Hatzfeld J.

Pathol Biol (Paris). 2006 Mar;54(2):94-9. Epub 2005 Sep 2. Review. French.

PMID:
16140469
10.

Comment on " 'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature".

Fortunel NO, Otu HH, Ng HH, Chen J, Mu X, Chevassut T, Li X, Joseph M, Bailey C, Hatzfeld JA, Hatzfeld A, Usta F, Vega VB, Long PM, Libermann TA, Lim B.

Science. 2003 Oct 17;302(5644):393; author reply 393. No abstract available.

11.

Long-term expansion of human functional epidermal precursor cells: promotion of extensive amplification by low TGF-beta1 concentrations.

Fortunel NO, Hatzfeld JA, Rosemary PA, Ferraris C, Monier MN, Haydont V, Longuet J, Brethon B, Lim B, Castiel I, Schmidt R, Hatzfeld A.

J Cell Sci. 2003 Oct 1;116(Pt 19):4043-52.

12.

Control of hematopoietic stem/progenitor cell fate by transforming growth factor-beta.

Fortunel NO, Hatzfeld JA, Monier MN, Hatzfeld A.

Oncol Res. 2003;13(6-10):445-53.

PMID:
12725536
13.

Specific dose-response effects of TGF-beta1 on developmentally distinct hematopoietic stem/progenitor cells from human umbilical cord blood.

Fortunel N, Hatzfeld J, Aoustin L, Batard P, Ducos K, Monier MN, Charpentier A, Hatzfeld A.

Hematol J. 2000;1(2):126-35. Erratum in: Hematol J 2000;1(3):218.

PMID:
11920180
14.

Fibrinogen cooperates with cytokines to induce interleukin-6 receptor mRNA expression in human hematopoietic CD34+ progenitors.

Hatzfeld A, Panterne B, Fortunel NO, Monier MN, Hatzfeld JA.

Eur Cytokine Netw. 2001 Mar;12(1):172-6.

15.

The high proliferative potential-quiescent (HPP-Q) cell assay allows an optimized evaluation of gene transfer efficiency into primitive hematopoietic stem/progenitor cells.

Ducos K, Hatzfeld A, Héron A, Fortunel N, Kisselev S, Héron C, Monier MN, Hatzfeld J.

Gene Ther. 2000 Oct;7(20):1790-4.

16.

Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis.

Fortunel NO, Hatzfeld A, Hatzfeld JA.

Blood. 2000 Sep 15;96(6):2022-36. Review.

PMID:
10979943
17.

p21(cip1) mRNA is controlled by endogenous transforming growth factor-beta1 in quiescent human hematopoietic stem/progenitor cells.

Ducos K, Panterne B, Fortunel N, Hatzfeld A, Monier MN, Hatzfeld J.

J Cell Physiol. 2000 Jul;184(1):80-5.

PMID:
10825236
18.

Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-beta type II receptor in a short-term in vitro assay.

Fortunel N, Hatzfeld J, Kisselev S, Monier MN, Ducos K, Cardoso A, Batard P, Hatzfeld A.

Stem Cells. 2000;18(2):102-11.

19.

TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation.

Batard P, Monier MN, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T, Hatzfeld A, Hatzfeld JA.

J Cell Sci. 2000 Feb;113 ( Pt 3):383-90.

20.

High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells.

Fortunel N, Batard P, Hatzfeld A, Monier MN, Panterne B, Lebkowski J, Hatzfeld J.

J Cell Sci. 1998 Jul;111 ( Pt 13):1867-75.

21.

Mitogenic effect of fibrinogen on hematopoietic cells: involvement of two distinct specific receptors, MFR and ICAM-1.

Héron A, Lévesque JP, Hatzfeld A, Kisselev S, Monier MN, Krief P, Hatzfeld J.

Biochem Biophys Res Commun. 1998 May 8;246(1):231-7.

PMID:
9600098
22.

IL-3, GM-CSF and CSF-1 modulate c-fms mRNA more rapidly in human early monocytic progenitors than in mature or transformed monocytic cells.

Panterne B, Hatzfeld A, Sansilvestri P, Cardoso A, Monier MN, Batard P, Hatzfeld J.

J Cell Sci. 1996 Jul;109 ( Pt 7):1795-801.

23.

Increased stable retroviral gene transfer in early hematopoietic progenitors released from quiescence.

Hatzfeld A, Batard P, Panterne B, Taieb F, Hatzfeld J.

Hum Gene Ther. 1996 Jan 20;7(2):207-13.

PMID:
8788171
24.

Early CD34high cells can be separated into KIThigh cells in which transforming growth factor-beta (TGF-beta) downmodulates c-kit and KITlow cells in which anti-TGF-beta upmodulates c-kit.

Sansilvestri P, Cardoso AA, Batard P, Panterne B, Hatzfeld A, Lim B, Lévesque JP, Monier MN, Hatzfeld J.

Blood. 1995 Sep 1;86(5):1729-35.

PMID:
7544639
25.

An improved panning technique for the selection of CD34+ human bone marrow hematopoietic cells with high recovery of early progenitors.

Cardoso AA, Watt SM, Batard P, Li ML, Hatzfeld A, Genevier H, Hatzfeld J.

Exp Hematol. 1995 May;23(5):407-12.

PMID:
7536682
26.

Additive effects of steel factor and antisense TGF-beta 1 oligodeoxynucleotide on CD34+ hematopoietic progenitor cells.

Li ML, Cardoso AA, Sansilvestri P, Hatzfeld A, Brown EL, Sookdeo H, Levesque JP, Clark SC, Hatzfeld J.

Leukemia. 1994 Mar;8(3):441-5.

PMID:
7510356
27.

Purification and release from quiescence of umbilical cord blood early progenitors reveal their potential to engraft adults.

Hatzfeld J, Batard P, Cardoso AA, Li ML, Panterne B, Sansilvestri P, Ginsbourg M, Levesque JP, Hatzfeld A.

Blood Cells. 1994;20(2-3):430-4; discussion 434-5.

PMID:
7538349
28.

The heparin binding PECAM-1 adhesion molecule is expressed by CD34+ hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes.

Watt SM, Williamson J, Genevier H, Fawcett J, Simmons DL, Hatzfeld A, Nesbitt SA, Coombe DR.

Blood. 1993 Nov 1;82(9):2649-63.

PMID:
7693043
29.

Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults.

Cardoso AA, Li ML, Batard P, Hatzfeld A, Brown EL, Levesque JP, Sookdeo H, Panterne B, Sansilvestri P, Clark SC, et al.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8707-11.

30.

Fibrinogen potentiates the effect of interleukin-3 on early human hematopoietic progenitors.

Zhou YQ, Levesque JP, Hatzfeld A, Cardoso AA, Li ML, Sansilvestri P, Hatzfeld J.

Blood. 1993 Aug 1;82(3):800-6.

PMID:
7687894
31.

[Positive and negative controls on hematopoietic progenitor development: models and facts].

Panterne B, Hatzfeld A, Zhou YQ, Li ML, Sansilvestri P, Cardoso A, Lévesque JP, Ginsbourg M, Batard P, Kiselev S, et al.

Nouv Rev Fr Hematol. 1993 Jun;35(3):281-3. French.

PMID:
8337145
32.

CSF-1 control of C-FMS expression in normal human bone marrow progenitors.

Panterne B, Zhou YQ, Hatzfeld J, Li ML, Levesque JP, Clark SC, Hatzfeld A.

J Cell Physiol. 1993 May;155(2):282-9.

PMID:
8482721
33.

Co-stimulatory effects of steel factor, the c-kit ligand, on purified human hematopoietic progenitors in low cell density culture.

Li ML, Cardoso A, Sansilvestri P, Hatzfeld A, Kisselev S, Batard P, Levesque JP, Hatzfeld J.

Nouv Rev Fr Hematol. 1993 Feb;35(1):81-6.

PMID:
7685520
34.

Human umbilical cord blood CD34+ cell purification with high yield of early progenitors.

Cardoso AA, Li ML, Batard P, Sansilvestri P, Hatzfeld A, Levesque JP, Lebkowski JS, Hatzfeld J.

J Hematother. 1993 Summer;2(2):275-9.

PMID:
7522882
35.

c-fos mRNA constitutive expression by mature human megakaryocytes.

Panterne B, Hatzfeld J, Blanchard JM, Levesque JP, Berthier R, Ginsbourg M, Hatzfeld A.

Oncogene. 1992 Nov;7(11):2341-4.

PMID:
1437157
36.

Cryopreservative effect of leupeptin on early human bone marrow progenitors.

Li ML, Panterne B, Levesque JP, Hatzfeld A, Hatzfeld J.

In Vitro Cell Dev Biol. 1992 Jun;28A(6):459-60.

PMID:
1634445
37.

Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides.

Hatzfeld J, Li ML, Brown EL, Sookdeo H, Levesque JP, O'Toole T, Gurney C, Clark SC, Hatzfeld A.

J Exp Med. 1991 Oct 1;174(4):925-9.

38.

DNA transfection in COS cells: a low-cost serum-free method compared to lipofection.

Lévesque JP, Sansilvestri P, Hatzfeld A, Hatzfeld J.

Biotechniques. 1991 Sep;11(3):313-4, 316-8.

PMID:
1931028
39.

Mitogenic properties of major extracellular proteins.

Lévesque JP, Hatzfeld A, Hatzfeld J.

Immunol Today. 1991 Aug;12(8):258-62. Review.

PMID:
1910446
40.

Human thymic epithelial cells produce interleukin-3.

Dalloul AH, Arock M, Fourcade C, Hatzfeld A, Bertho JM, Debré P, Mossalayi MD.

Blood. 1991 Jan 1;77(1):69-74.

PMID:
1984804
41.

The down-regulation of the mitogenic fibrinogen receptor (MFR) in serum-containing medium does not occur in defined medium.

Levesque JP, Hatzfeld A, Domart I, Hatzfeld J.

Exp Cell Res. 1990 Feb;186(2):257-63.

PMID:
2404772
43.

Interleukin-3 and interleukin-1 alpha allow earlier bone marrow progenitors to respond to human colony-stimulating factor 1.

Zhou YQ, Stanley ER, Clark SC, Hatzfeld JA, Levesque JP, Federici C, Watt SM, Hatzfeld A.

Blood. 1988 Dec;72(6):1870-4.

PMID:
3264191
44.

Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.

Hatzfeld A, Fischer E, Levesque JP, Perrin R, Hatzfeld J, Kazatchkine MD.

J Immunol. 1988 Jan 1;140(1):170-5.

PMID:
2826586
45.

Evidence for two functionally different fibrinogen receptors on hemopoietic cells: the glycoprotein IIb-IIIa and the mitogenic fibrinogen receptor.

Levesque JP, Hatzfeld A, Hudry-Clergeon G, Wilner GD, Hatzfeld J.

J Cell Physiol. 1987 Aug;132(2):303-10.

PMID:
3624317
46.

[C3 stimulates the proliferation of human pre-B Raji cells].

Hatzfeld J, Charriaut-Marlangue C, Levesque JP, Barel M, Stancou R, Krikorian L, Hatzfeld A, Frade R.

Ann Inst Pasteur Immunol. 1987 May-Jun;138(3):451-5. French.

PMID:
3498498
47.

Fibrinogen mitogenic effect on hemopoietic cell lines: control via receptor modulation.

Levesque JP, Hatzfeld A, Hatzfeld J.

Proc Natl Acad Sci U S A. 1986 Sep;83(17):6494-8.

48.

Dexamethasone-induced stimulation of arachidonic acid release by U937 cells grown in defined medium.

Duval D, Lynde P, Hatzfeld A, Hatzfeld J.

Biochim Biophys Acta. 1986 Jul 11;887(2):204-13.

PMID:
3087432
49.
50.

Differential reactivity of human lymphocytes allosensitized in vitro in hormonally defined medium or medium supplemented with plasma.

Bensussan A, Soulie A, Hatzfeld J, Hatzfeld A, Sasportes M.

Cell Immunol. 1983 Oct 15;81(2):441-6.

PMID:
6227394

Supplemental Content

Loading ...
Support Center